Chandramani Singh - Concepedia

Author

Chandramani Singh

All India Institute of Medical Sciences ORCID

Also Known As

C M Singh, C Singh, C. M. Singh, C.M. Singh, CM Singh, ChandraMani Singh, Chandramani Singh, Charnpreet Singh, Chetna singh -, Chhavi Singh

100

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

All India Institute of Medical Sciences Bharat Biotech (India)Nizam's Institute of Medical Sciences Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences ICMR-National Institute of Virology

About

Chandramani Singh is an author at All India Institute of Medical Sciences specializing in medicine, vaccine safety, and covid-19.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.1K
2	Public Health	3	3	82
3	Epidemiology	2	2	48
4	Health Sciences	1	1	10
5	Child Development	1	1	10

Chandramani Singh

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	433
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial Raches Ella, Siddharth Reddy, Harsh Jogdand, The Lancet Infectious Diseases	2021	360
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial Raches Ella, Siddarth Reddy, William C. Blackwelder, The Lancet VaccinationVaccine SafetyVaccine DevelopmentImmunologyInterim Results	2021	358
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial Raches Ella, Siddarth Reddy, William C. Blackwelder, ImmunodeficienciesImmunologyInactivated Sars-cov-2 VaccineImmunotherapyCovid-19	2021	79
Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®) Chandramani Singh, Savita Verma, Prabhakar Reddy, npj Vaccines	2023	74
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, EBioMedicine VaccinationVaccine SafetyVaccinologyPhase-2 Clinical TrialsVaccine Development	2022	73
WASH practices and its association with nutritional status of adolescent girls in poverty pockets of eastern India Aparajita Chattopadhyay, Vani Sethi, Varsha P. Nagargoje, BMC Women s Health	2019	62
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report Raches Ella, Siddharth Reddy, Harsh Jogdand, ImmunodeficienciesViral ImmunityImmunologyDifferent FormulationsImmunotherapeutics	2020	38
Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India Chandramani Singh, Bijaya Nanda Naik, Sanjay Pandey, Epidemiology and Infection Corona Virus Disease-19Covid-19 EpidemiologyCovid-19Preventive MedicineEastern State	2021	38
Prevalence of specific micronutrient deficiencies in urban school going children and adolescence of India: A multicenter cross-sectional study Shally Awasthi, Divas Kumar, Abbas Ali Mahdi, PLoS ONE	2022	38

Page 1